Wiskott-Aldrich syndrome presenting with a clinical picture mimicking juvenile myelomonocytic leukaemia

Pediatric Blood and Cancer

Volumn 60, Issue 5, 2013, Pages 836-841

  Yoshimi, Ayami ^a   Kamachi, Yoshiro ^b   Imai, Kosuke ^c   Watanabe, Nobuhiro ^d   Nakadate, Hisaya ^e   Kanazawa, Takashi ^f   Ozono, Shuichi ^g   Kobayashi, Ryoji ^h   Yoshida, Misa ⁱ   Kobayashi, Chie ^j   Hama, Asahito ^b   Muramatsu, Hideki ^b   Sasahara, Yoji ^k   Jakob, Marcus ^l   Morio, Tomohiro ^c   Ehl, Stephan ^a   Manabe, Atsushi ^m   Niemeyer, Charlotte ^a   Kojima, Seiji ^b  

^a UNIVERSITY OF FREIBURG   (Germany)

^b NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^d JAPANESE RED CROSS NAGOYA FIRST HOSPITAL   (Japan)

^e KITASATO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f GUNMA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^g KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^h SAPPORO HOKUYU HOSPITAL   (Japan)

ⁱ KANAGAWA CHILDREN'S MEDICAL CENTER   (Japan)

^j UNIVERSITY OF TSUKUBA   (Japan)

^k TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^l UNIVERSITY OF REGENSBURG   (Germany)

^m ST LUKE'S INTERNATIONAL HOSPITAL   (Japan)

more..

Author keywords

Children; Juvenile myelomonocytic leukaemia; Wiskott Aldrich syndrome

Indexed keywords

K RAS PROTEIN; MERCAPTOPURINE; PROTEIN TYROSINE PHOSPHATASE SHP 2; WISKOTT ALDRICH SYNDROME PROTEIN;

ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANEMIA; ARTICLE; BLOODY DIARRHEA; CANCER DIAGNOSIS; CLINICAL ARTICLE; DIAGNOSTIC TEST; DISEASE COURSE; ECZEMA; ERYTHROID PRECURSOR CELL; FLOW CYTOMETRY; GENE MUTATION; GRAFT FAILURE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFANT; JUVENILE MYELOMONOCYTIC LEUKEMIA; LEUKOCYTOSIS; MALE; MONOCYTOSIS; MUTATIONAL ANALYSIS; MYELODYSPLASTIC SYNDROME; MYELOID PROGENITOR CELL; NONSENSE MUTATION; ONCOGENE K RAS; ONCOGENE N RAS; PRIORITY JOURNAL; RECTUM HEMORRHAGE; RECURRENT INFECTION; SPLENOMEGALY; THROMBOCYTE STRUCTURE; THROMBOCYTE TRANSFUSION; THROMBOCYTE VOLUME; THROMBOCYTOPENIA; WISKOTT ALDRICH SYNDROME;

BONE MARROW; DIAGNOSIS, DIFFERENTIAL; DNA MUTATIONAL ANALYSIS; ERYTHROID PRECURSOR CELLS; GTP PHOSPHOHYDROLASES; HUMANS; INFANT; INFANT, NEWBORN; LEUKEMIA, MYELOMONOCYTIC, JUVENILE; LEUKOCYTOSIS; MALE; MEMBRANE PROTEINS; MYELOID PROGENITOR CELLS; PROTEIN TYROSINE PHOSPHATASE, NON-RECEPTOR TYPE 11; PROTO-ONCOGENE PROTEINS; RAS PROTEINS; THROMBOCYTOPENIA; WISKOTT-ALDRICH SYNDROME; WISKOTT-ALDRICH SYNDROME PROTEIN;

EID: 84875000548     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24359     Document Type: Article

References (42)

1. Bosticardo M, Marangoni F, Aiuti A, et al. Recent advances in understanding the pathophysiology of Wiskott-Aldrich syndrome. Blood 2009; 113: 6288-6295.
2. Thrasher AJ, Burns SO. WASP: A key immunological multitasker. Nat Rev Immunol 2010; 10: 182-192.
3. Derry JM, Ochs HD, Francke U. Isolation of a novel gene mutated in Wiskott-Aldrich syndrome. Cell 1994; 78: 635-644.
4. Imai K, Morio T, Zhu Y, et al. Clinical course of patients with WASP gene mutations. Blood 2004; 103: 456-464.
5. Jin Y, Mazza C, Christie JR, et al. Mutations of the Wiskott-Aldrich syndrome protein (WASP): Hotspots, effect on transcription, and translation and phenotype/genotype correlation. Blood 2004; 104: 4010-4019.
6. Devriendt K, Kim AS, Mathijs G, et al. Constitutively activating mutation in WASP causes X-linked severe congenital neutropenia. Nat Genet 2001; 27: 313-317.
7. Ancliff PJ, Blundell MP, Cory GO, et al. Two novel activating mutations in the Wiskott-Aldrich syndrome protein result in congenital neutropenia. Blood 2006; 108: 2182-2189.
8. Hasle H, Wadsworth LD, Massing BG, et al. A population-based study of childhood myelodysplastic syndrome in British Columbia, Canada. Br J Haematol 1999; 106: 1027-1032.
9. Baumann I, Benett J, Niemeyer CM, et al. Juvenile myelomonocytic leukemia. In: Swerdlow S, Campo E, Harris N, et al, editors. WHO classification of tumors of haematopoietic and lymphoid tissues. Lyon: IARC Press; 2008. 82-86.
10. Niemeyer CM, Arico M, Basso G, et al. Chronic myelomonocytic leukemia in childhood: A retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS). Blood 1997; 89: 3534-3543.
11. Yoshimi A, Kojima S, Hirano N. Juvenile myelomonocytic leukemia: Epidemiology, etiopathogenesis, diagnosis, and management considerations. Paediatr Drugs 2010; 12: 11-21.
12. Tartaglia M, Niemeyer CM, Song X, et al. Somatic PTPN11 mutations in juvenile myelomonocytic leukemia, myelodysplastic syndromes and acute myeloid leukemia. Nat Genet 2003; 34: 148-150.
13. Flotho C, Valcamonica S, Mach-Pascula S, et al. RAS mutations and clonality analysis in children with juvenile myelomonocytic leukemia (JMML). Leukemia 1999; 13: 32-37.
14. Side L, Taylor B, Cayouette M, et al. Homozygous inactivation of the NF1 gene in bone marrow cells from children with neurofibromatosis type 1 and malignant myeloid disorders. N Engl J Med 1997; 336: 1713-1720.
15. Le DT, Kong N, Zhu Y, et al. Somatic inactivation of Nf1 in hematopoietic cells results in a progressive myeloproliferative disorder. Blood 2004; 103: 4243-4250.
16. Niemeyer CM, Kang MW, Shin DH, et al. Germline CBL mutations cause developmental abnormalities and predispose to juvenile myelomonocytic leukemia. Nat Genet 2010; 42: 794-800.
17. Loh ML, Sakai DS, Flotho C, et al. Mutations in CBL occur frequently in juvenile myelomonocytic leukemia. Blood 2009; 114: 1859-1863.
18. Muramatsu H, Makishima H, Jankowska AM, et al. Mutations of an E3 ubiquitin ligase c-Cbl but not TET2 mutations are pathogenic in juvenile myelomonocytic leukemia. Blood 2010; 115: 1969-1975.
19. Kajiwara M, Nonoyama S, Eguchi M, et al. WASP is involved in proliferation and differentiation of human haemopoietic progenitors in vitro. Br J Haematol 1999; 107: 254-262.
20. Watanabe N, Yoshimi A, Kamachi Y, et al. Wiskott-Aldrich syndrome is an important differential diagnosis in male infants with juvenile myelomonocytic leukemialike features. J Pediatr Hematol Oncol 2007; 29: 836-838.
21. Sano H, Kobayashi R, Suzuki D, et al. Wiskott-Aldrich syndrome with unusual clinical features similar to juvenile myelomonocytic leukemia. Int J Hematol 2012; 96: 279-283.
22. Yamada M, Ariga T, Kawamura N, et al. Determination of carrier status for the Wiskott-Aldrich syndrome by flow cytometric analysis of Wiskott-Aldrich syndrome protein expression in peripheral blood mononuclear cells. J Immunol 2000; 165: 1119-1122.
23. Itoh S, Nonoyama S, Morio T, et al. Mutations of the WASP gene in 10 Japanese patients with Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Int J Hematol 2000; 71: 79-83.
24. Yoshida N, Yagasaki H, Xu Y, et al. Correlation of clinical features with the mutational status of GM-CSF signaling pathway-related genes in juvenile myelomonocytic leukemia. Pediatr Res 2009; 65: 334-340.
25. Yamamoto T, Isomura M, Xu Y, et al. PTPN11, RAS and FLT3 mutations in childhood acute lymphoblastic leukemia. Leuk Res 2006; 30: 1085-1089.
26. Mitani K, Hangaishi A, Imamura N, et al. No concomitant occurrence of the N-ras and p53 gene mutations in myelodysplastic syndromes. Leukemia 1997; 11: 863-865.
27. Tartaglia M, Martinelli S, Cazzaniga G, et al. Genetic evidence for lineage-related and differentiation stage-related contribution of somatic PTPN11 mutations to leukemogenesis in childhood acute leukemia. Blood 2004; 104: 307-313.
28. Emanuel PD, Bates LJ, Castleberry RP, et al. Selective hypersensitivity to granulocyte-macrophage colony-stimulating factor by juvenile chronic myeloid leukemia hematopoietic progenitors. Blood 1991; 77: 925-929.
29. Emanuel PD, Bates LJ, Zhu SW, et al. The role of monocyte-derived hemopoietic growth factors in the regulation of myeloproliferation in juvenile chronic myelogenous leukemia. Exp Hematol 1991; 19: 1017-1024.
30. Jo EK, Futatani T, Kanegane H, et al. Mutational analysis of the WASP gene in 2 Korean families with Wiskott-Aldrich syndrome. Int J Hematol 2003; 78: 40-44.
31. Qasim W, Gilmour KC, Heath S, et al. Protein assays for diagnosis of Wiskott-Aldrich syndrome and X-linked thrombocytopenia. Br J Haematol 2001; 113: 861-865.
32. Lemahieu V, Gastier JM, Francke U. Novel mutations in the Wiskott-Aldrich syndrome protein gene and their effects on transcriptional, translational, and clinical phenotypes. Hum Mutat 1999; 14: 54-66.
33. Ariga T, Yamada M, Sakiyama Y. Mutation analysis of five Japanese families with Wiskott-Aldrich syndrome and determination of the family members' carrier status using three different methods. Pediatr Res 1997; 41: 535-540.
34. Patel PD, Samanich JM, Mitchell WB, et al. A unique presentation of Wiskott-Aldrich syndrome in relation to platelet size. Pediatr Blood Cancer 2011; 56: 1127-1129.
35. Knox-Macaulay HH, Bashawri L, Davies KE. X linked recessive thrombocytopenia. J Med Genet 1993; 30: 968-969.
36. Manabe A, Yoshimasu T, Ebihara Y, et al. Viral infections in juvenile myelomonocytic leukemia: Prevalence and clinical implications. J Pediatr Hematol Oncol 2004; 26: 636-641.
37. Herrod HG, Dow LW, Sullivan JL. Persistent Epstein-Barr virus infection mimicking juvenile chronic myelogenous leukemia: Immunologic and hematologic studies. Blood 1983; 61: 1098-1104.
38. Karow A, Baumann I, Niemeyer CM. Morphologic differential diagnosis of juvenile myelomonocytic leukemia-pitfalls apart from viral infection. J Pediatr Hematol Oncol 2009; 31: 380.
39. Zhang H, Schaff UY, Green CE, et al. Impaired integrin-dependent function in Wiskott-Aldrich syndrome protein-deficient murine and human neutrophils. Immunity 2006; 25: 285-295.
40. Taylor MD, Sadhukhan S, Kottangada P, et al. Nuclear role of WASp in the pathogenesis of dysregulated TH1 immunity in human Wiskott-Aldrich syndrome. Sci Transl Med 2010; 2: 37ra44.
41. Westerberg LS, Meelu P, Baptista M, et al. Activating WASP mutations associated with X-linked neutropenia result in enhanced actin polymerization, altered cytoskeletal responses, and genomic instability in lymphocytes. J Exp Med 2010; 207: 1145-1152.
42. Moulding DA, Blundell MP, Spiller DG, et al. Unregulated actin polymerization by WASp causes defects of mitosis and cytokinesis in X-linked neutropenia. J Exp Med 2007; 204: 2213-2224.